Compare BCSF & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCSF | STTK |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 838.7M | 792.9M |
| IPO Year | 2015 | 2020 |
| Metric | BCSF | STTK |
|---|---|---|
| Price | $11.09 | $6.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $12.63 | ★ $14.67 |
| AVG Volume (30 Days) | 474.3K | ★ 864.5K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | ★ 17.12% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ 0.27 | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $41.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.95 | $1.70 |
| 52 Week High | $14.70 | $8.33 |
| Indicator | BCSF | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 60.14 |
| Support Level | N/A | $6.75 |
| Resistance Level | $13.74 | $7.75 |
| Average True Range (ATR) | 0.20 | 0.39 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 16.28 | 90.10 |
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.